Zhengye Biotechnology Holding Limited (ZYBT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZYBT SEC filings page.
Zhengye Biotechnology Holding Limited (ZYBT) reported $16.6M in revenue for fiscal year 2025, down 34.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A margin collapse exposed a cash-flow disconnect, with the business moving from profitable operations to losses despite positive cash generation.
Revenue fell from$25.5M in FY2024 to$16.6M in FY2025, while gross margin dropped from49.0% to20.5% . That simultaneous deterioration in volume and unit economics points to a deeper change in business performance than a simple slowdown.
Cash conversion diverged sharply from reported earnings: operating cash flow remained positive at
Free cash flow declined from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Zhengye Biotechnology Holding Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Zhengye Biotechnology Holding Limited has an operating margin of -60.6%, meaning the company loses $61 on every $100 of revenue. This results in a profitability score of 14/100. This is down from 8.8% the prior year.
Zhengye Biotechnology Holding Limited's revenue declined 34.8% year-over-year, from $25.5M to $16.6M. This contraction results in a growth score of 2/100.
Zhengye Biotechnology Holding Limited carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 85/100, indicating a strong balance sheet with room for future borrowing.
Zhengye Biotechnology Holding Limited's current ratio of 1.14 is below the typical benchmark, resulting in a score of 26/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Zhengye Biotechnology Holding Limited converts 10.6% of revenue into free cash flow ($1.8M). This strong cash generation earns a score of 72/100.
Zhengye Biotechnology Holding Limited posts a -27.9% return on equity (ROE), meaning it loses $28 for every $100 of shareholders' equity. This results in a returns score of 17/100. This is down from 4.0% the prior year.
Zhengye Biotechnology Holding Limited scores 2.21, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($77.2M) relative to total liabilities ($18.6M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Zhengye Biotechnology Holding Limited passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Zhengye Biotechnology Holding Limited reported a net loss of $10.0M while generating $1.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Zhengye Biotechnology Holding Limited reported an operating loss of $10.1M against $486K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Zhengye Biotechnology Holding Limited held $7.2M in cash against $1.4M in long-term debt as of Q4 2025, with $17.2M of liabilities due within a year.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
ZYBT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
ZYBT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F |
|---|---|---|---|
| Total Assets | $62.4M-7.6% | $70.4M | $67.6M |
| Current Assets | $19.6M-19.2% | $28.1M | $24.3M |
| Cash & Equivalents | $7.2M+182.3% | $6.4M | $2.5M |
| Short-Term Investments | $223K+13.2% | $282K | $197K |
| Inventory | $5.6M-29.8% | $7.5M | $8.0M |
| Accounts Receivable | $2.6M-67.6% | $5.2M | $8.2M |
| Long-Term Investments | $0 | $0 | $0 |
| Total Liabilities | $18.6M-3.7% | $19.5M | $19.3M |
| Current Liabilities | $17.2M-7.5% | $18.8M | $18.6M |
| Non-Current Liabilities | $1.3M+101.8% | $656K | $658K |
| Long-Term Debt | $1.4M+107.6% | $684K | $658K |
| Total Equity | $35.7M-8.2% | $41.7M | $38.9M |
| Retained Earnings | -$3.1M-147.0% | $3.7M | $6.6M |
Not reported in any period shown, so not listed: Goodwill.
ZYBT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
ZYBT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Zhengye Biotechnology Holding Limited ZYBT | FY2025 | $16.6M | -$10.0M | -60.0% | $77.2M | 36/100 |
| Emergent Biosolutions Inc EBS | FY2025 | $742.9M | $52.6M | 7.1% | $331.2M | 36/100 |
| Eton Pharmaceuticals ETON | FY2025 | $80.0M | -$4.6M | -5.8% | $1.8B | 50/100 |
| Canopy Growth Corp CGC | FY2026 | N/A | -$189.0M | N/A | $435.0M | — |
| Kamada Ltd KMDA | FY2025 | $180.5M | $20.2M | 11.2% | $484.6M | 41/100 |
| Evolus EOLS | FY2025 | $297.2M | -$51.6M | -17.4% | $598.4M | 34/100 |
Where Zhengye Biotechnology Holding Limited Ranks
Frequently Asked Questions
What is Zhengye Biotechnology Holding Limited's annual revenue?
Zhengye Biotechnology Holding Limited (ZYBT) reported $16.6M in total revenue for fiscal year 2025. This represents a -34.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Zhengye Biotechnology Holding Limited's revenue growing?
Zhengye Biotechnology Holding Limited (ZYBT) revenue declined by 34.8% year-over-year, from $25.5M to $16.6M in fiscal year 2025.
Is Zhengye Biotechnology Holding Limited profitable?
No, Zhengye Biotechnology Holding Limited (ZYBT) reported a net income of -$10.0M in fiscal year 2025, with a net profit margin of -60.0%.
What is Zhengye Biotechnology Holding Limited's EBITDA?
Zhengye Biotechnology Holding Limited (ZYBT) had EBITDA of -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Zhengye Biotechnology Holding Limited have?
As of fiscal year 2025, Zhengye Biotechnology Holding Limited (ZYBT) had $7.2M in cash and equivalents against $1.4M in long-term debt.
What is Zhengye Biotechnology Holding Limited's gross margin?
Zhengye Biotechnology Holding Limited (ZYBT) had a gross margin of 20.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Zhengye Biotechnology Holding Limited's operating margin?
Zhengye Biotechnology Holding Limited (ZYBT) had an operating margin of -60.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Zhengye Biotechnology Holding Limited's net profit margin?
Zhengye Biotechnology Holding Limited (ZYBT) had a net profit margin of -60.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Zhengye Biotechnology Holding Limited's return on equity (ROE)?
Zhengye Biotechnology Holding Limited (ZYBT) has a return on equity of -27.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Zhengye Biotechnology Holding Limited's free cash flow?
Zhengye Biotechnology Holding Limited (ZYBT) generated $1.8M in free cash flow during fiscal year 2025. This represents a -53.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Zhengye Biotechnology Holding Limited's operating cash flow?
Zhengye Biotechnology Holding Limited (ZYBT) generated $1.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Zhengye Biotechnology Holding Limited's total assets?
Zhengye Biotechnology Holding Limited (ZYBT) had $62.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Zhengye Biotechnology Holding Limited's capital expenditures?
Zhengye Biotechnology Holding Limited (ZYBT) invested $144K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Zhengye Biotechnology Holding Limited spend on research and development?
Zhengye Biotechnology Holding Limited (ZYBT) invested $2.6M in research and development during fiscal year 2025.
What is Zhengye Biotechnology Holding Limited's current ratio?
Zhengye Biotechnology Holding Limited (ZYBT) had a current ratio of 1.14 as of fiscal year 2025, which is considered adequate.
What is Zhengye Biotechnology Holding Limited's debt-to-equity ratio?
Zhengye Biotechnology Holding Limited (ZYBT) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Zhengye Biotechnology Holding Limited's return on assets (ROA)?
Zhengye Biotechnology Holding Limited (ZYBT) had a return on assets of -16.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Zhengye Biotechnology Holding Limited's P/E ratio?
Zhengye Biotechnology Holding Limited (ZYBT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $77.2M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Zhengye Biotechnology Holding Limited's price-to-sales ratio?
Zhengye Biotechnology Holding Limited (ZYBT) trades at 4.6x sales, its market capitalization divided by revenue of $16.6M revenue, FY2025. The market capitalization is $77.2M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Zhengye Biotechnology Holding Limited's Altman Z-Score?
Zhengye Biotechnology Holding Limited (ZYBT) has an Altman Z-Score of 2.21, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Zhengye Biotechnology Holding Limited's Piotroski F-Score?
Zhengye Biotechnology Holding Limited (ZYBT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Zhengye Biotechnology Holding Limited's earnings high quality?
Zhengye Biotechnology Holding Limited (ZYBT) reported a net loss of $10.0M while generating $1.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Zhengye Biotechnology Holding Limited cover its interest payments?
Zhengye Biotechnology Holding Limited (ZYBT) reported an operating loss of $10.1M against $486K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Zhengye Biotechnology Holding Limited?
Zhengye Biotechnology Holding Limited (ZYBT) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.